Investors

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS), and spinal muscular atrophy (SMA) Type 3. 

The US FDA approved FIRDAPSE® (amifampridine) tablets for use in adults with LEMS on November 28, 2018, and FIRDAPSE was commercially available in January 2019

Catalyst is in the early stages of developing a long acting formulation of FIRDAPSE